Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Darolutamide Tablets

Approved

化学药品

Darolutamide Tablets

BAYER HEALTHCARE PHARMACEUTICALS INC.🇨🇳 National Medical Products Administration

Approval Date: Sep 3, 2025
Approval ID: 887ldOdKIsl
Company: BAYER HEALTHCARE PHARMACEUTICALS INC.
Type: 化学药品

Approval Details

Approval Id: 887ldOdKIsl
Approval Number: 国药准字HJ20210010
Generic Name: 达罗他胺片
Generic Name En: Darolutamide Tablets
Trade Name: 诺倍戈
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 300mg
Reg Date: 2025-09-03
Expired Date: 2030-09-02
Company Name: BAYER HEALTHCARE PHARMACEUTICALS INC.
Company Detail Path: /organization/bayer-healthcare-pharmaceuticals-inc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 3, 2025

Approval ID

887ldOdKIsl

Type

化学药品

Back to NMPA Approvals

诺倍戈 - NMPA Drug Approval Details